StreetInsider.com News Articles

Jones Trading Starts Seaport Therapeutics (SPTX) at Buy

Tue, 25 Aug 2026 16:17:38 -0400

(Updated - August 25, 2026 4:17 PM EDT)

Jones Trading analyst Justin Walsh initiates coverage on Seaport Therapeutics (NASDAQ: SPTX) with a Buy rating and a price target of $32.00.

The analyst comments "We are initiating coverage of Seaport Therapeutics (SPTX) with a Buy rating and $32 price target. Seaport is a clinical-stage biotechnology company developing novel treatments for depression, anxiety, and other neuropsychiatric disorders using its proprietary Glyph lymphatic-targeting prodrug platform. The company's strategy is to apply Glyph to clinically validated molecules whose therapeutic potential has historically been constrained by poor bioavailability, extensive first-pass metabolism, pharmacokinetic variability, tolerability concerns, or intellectual-property

Jones Trading Starts Seaport Therapeutics (SPTX) at Buy

Tue, 25 Aug 2026 16:17:38 -0400

(Updated - August 25, 2026 4:17 PM EDT)

Jones Trading analyst Justin Walsh initiates coverage on Seaport Therapeutics (NASDAQ: SPTX) with a Buy rating and a price target of $32.00.

H.C. Wainwright Reiterates Buy Rating on Seaport Therapeutics (SPTX)

Thu, 20 Aug 2026 06:58:28 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $50.00 price target on Seaport Therapeutics (NASDAQ: SPTX).

The analyst commented: "We recently spoke with Seaport Therapeutics management about various developments across the spectrum of neuropsychiatry, particularly pertaining to the competitive landscape in major depression and the re-emergence of psychedelics. In particular, we feel that the top-line data from MapLight Therapeutics' (MPLT; Buy) ML-007C-MA candidate has somewhat reduced long-term competitive pressure for Seaport, particularly with respect to GlyphAllo, while the augmented profiles of various psychedelic candidates in late-stage development may raise investor awareness of Seaport's Glyph2BLSD candidate. Glyph2BLSD is a non-hallucinogenic

Form SCHEDULE 13G Seaport Therapeutics, Filed by: PureTech LYT, Inc.

Fri, 14 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26931618.html

Form SCHEDULE 13G Seaport Therapeutics, Filed by: PureTech LYT, Inc.

Fri, 14 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26931618.html

Seaport Therapeutics (SPTX) PT Lowered to $44 at JPMorgan

Wed, 05 Aug 2026 08:17:20 -0400

JPMorgan analyst Tessa Romero lowered the price target on Seaport Therapeutics (NASDAQ: SPTX) to $44.00 (from $45.00) while maintaining a Overweight rating.

Form SCHEDULE 13G Seaport Therapeutics, Filed by: Zohar Daphne

Wed, 05 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260805/26870684.html

Form SCHEDULE 13G Seaport Therapeutics, Filed by: Zohar Daphne

Wed, 05 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260805/26870684.html

Form SCHEDULE 13G Seaport Therapeutics, Filed by: PAUL STEVEN M

Wed, 05 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260805/26869489.html

Form SCHEDULE 13G Seaport Therapeutics, Filed by: PAUL STEVEN M

Wed, 05 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260805/26869489.html

H.C. Wainwright Reiterates Buy Rating on Seaport Therapeutics (SPTX)

Tue, 04 Aug 2026 06:54:00 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $50.00 price target on Seaport Therapeutics (NASDAQ: SPTX).

The analyst commented: "Seaport Therapeutics continues to advance its two most mature clinical-stage assets, GlyphAllo (based on allopregnanolone) and GlyphAgo (based on agomelatine). The company is actively enrolling patients in BUOY-1, a two-arm, global, randomized, double-blind, placebo-controlled, potentially registration-enabling Phase 2b trial investigating the safety and efficacy of GlyphAllo in patients with MDD with or without anxious distress. Top-line data from the BUOY-1 trial are slated for release in 1H27. A Phase 1 driving simulation trial of GlyphAllo in healthy volunteers is slated

Form 10-Q Seaport Therapeutics, For: Jun 30

Mon, 03 Aug 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260803/26853821.html

Form 8-K Seaport Therapeutics, For: Aug 03

Mon, 03 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260803/26853751.html

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Mon, 03 Aug 2026 07:00:00 -0400

Enrollment in Phase 2b BUOY-1 trial of GlyphAllo™ in major depressive disorder (MDD) is on track with topline data expected in 1H 2027

Phase 1 driving simulation trial of GlyphAllo on track to report topline data in 2H 2026

Following positive data from completed Phase 1 proof-of-concept trial of GlyphAgo™, Company plans to initiate Phase 2a trial in patients with generalized anxiety disorder (GAD) and sleep disturbance in 2H 2026, and Phase 2b trial in patients with GAD in 1H 2027

Glyph2BLSD™, a novel non-hallucinogenic neuroplastogen, is on track to complete first-in-human-enabling studies by the end of 2027

Upsized

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Mon, 03 Aug 2026 07:00:00 -0400

Enrollment in Phase 2b BUOY-1 trial of GlyphAllo™ in major depressive disorder (MDD) is on track with topline data expected in 1H 2027
Phase 1 driving simulation trial of GlyphAllo on track to report topline data in 2H 2026
Following positive data from completed Phase 1 proof-of-concept trial of GlyphAgo™, Company plans to initiate Phase 2a trial in patients with generalized anxiety disorder (GAD) and sleep disturbance in 2H 2026, and Phase 2b trial in patients with GAD in 1H 2027
Glyph2BLSD™, a novel non-hallucinogenic neuroplastogen, is on track to complete first-in-human-enabling studies by the end of 2027
Upsized

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Mon, 03 Aug 2026 07:00:00 -0400

Enrollment in Phase 2b BUOY-1 trial of GlyphAllo™ in major depressive disorder (MDD) is on track with topline data expected in 1H 2027
Phase 1 driving simulation trial of GlyphAllo on track to report topline data in 2H 2026
Following positive data from completed Phase 1 proof-of-concept trial of GlyphAgo™, Company plans to initiate Phase 2a trial in patients with generalized anxiety disorder (GAD) and sleep disturbance in 2H 2026, and Phase 2b trial in patients with GAD in 1H 2027
Glyph2BLSD™, a novel non-hallucinogenic neuroplastogen, is on track to complete first-in-human-enabling studies by the end of 2027
Upsized

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Mon, 03 Aug 2026 07:00:00 -0400

Enrollment in Phase 2b BUOY-1 trial of GlyphAllo™ in major depressive disorder (MDD) is on track with topline data expected in 1H 2027
Phase 1 driving simulation trial of GlyphAllo on track to report topline data in 2H 2026
Following positive data from completed Phase 1 proof-of-concept trial of GlyphAgo™, Company plans to initiate Phase 2a trial in patients with generalized anxiety disorder (GAD) and sleep disturbance in 2H 2026, and Phase 2b trial in patients with GAD in 1H 2027
Glyph2BLSD™, a novel non-hallucinogenic neuroplastogen, is on track to complete first-in-human-enabling studies by the end of 2027
Upsized

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Mon, 03 Aug 2026 07:00:00 -0400

Enrollment in Phase 2b BUOY-1 trial of GlyphAllo™ in major depressive disorder (MDD) is on track with topline data expected in 1H 2027
Phase 1 driving simulation trial of GlyphAllo on track to report topline data in 2H 2026
Following positive data from completed Phase 1 proof-of-concept trial of GlyphAgo™, Company plans to initiate Phase 2a trial in patients with generalized anxiety disorder (GAD) and sleep disturbance in 2H 2026, and Phase 2b trial in patients with GAD in 1H 2027
Glyph2BLSD™, a novel non-hallucinogenic neuroplastogen, is on track to complete first-in-human-enabling studies by the end of 2027
Upsized

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Mon, 03 Aug 2026 07:00:00 -0400

Enrollment in Phase 2b BUOY-1 trial of GlyphAllo™ in major depressive disorder (MDD) is on track with topline data expected in 1H 2027
Phase 1 driving simulation trial of GlyphAllo on track to report topline data in 2H 2026
Following positive data from completed Phase 1 proof-of-concept trial of GlyphAgo™, Company plans to initiate Phase 2a trial in patients with generalized anxiety disorder (GAD) and sleep disturbance in 2H 2026, and Phase 2b trial in patients with GAD in 1H 2027
Glyph2BLSD™, a novel non-hallucinogenic neuroplastogen, is on track to complete first-in-human-enabling studies by the end of 2027
Upsized

H.C. Wainwright Starts Seaport Therapeutics (SPTX) at Buy

Wed, 15 Jul 2026 07:30:25 -0400
(Updated - July 15, 2026 7:30 AM EDT)
H.C. Wainwright analyst Raghuram Selvaraju initiates coverage on Seaport Therapeutics (NASDAQ: SPTX) with a Buy rating and a price target of $50.00.
The analyst comments "Optimized delivery to disrupt depression and anxiety. We are initiating coverage of Seaport Therapeutics, an emerging biopharmaceutical company focusing on development of next-generation therapies for depression and anxiety, with a Buy rating and 12-month price target of $50 per share. The company has established a highly novel and potentially disruptive technology platform, Glyph, which utilizes lymphatic system delivery to optimize the bioavailability of well-known existing drugs. In bypassing first-pass

H.C. Wainwright Starts Seaport Therapeutics (SPTX) at Buy

Wed, 15 Jul 2026 07:30:25 -0400
(Updated - July 15, 2026 7:30 AM EDT)
H.C. Wainwright analyst Raghuram Selvaraju initiates coverage on Seaport Therapeutics (NASDAQ: SPTX) with a Buy rating and a price target of $50.00.
The analyst comments "Optimized delivery to disrupt depression and anxiety. We are initiating coverage of Seaport Therapeutics, an emerging biopharmaceutical company focusing on development of next-generation therapies for depression and anxiety, with a Buy rating and 12-month price target of $50 per share. The company has established a highly novel and potentially disruptive technology platform, Glyph, which utilizes lymphatic system delivery to optimize the bioavailability of well-known existing drugs. In bypassing first-pass

Form 4 Seaport Therapeutics, For: Jun 22 Filed by: HOMBACH ROBERT J.

Wed, 24 Jun 2026 06:05:00 -0400
si-local-file:///var/storage/secattach/20260624/26681787.html

Stifel Reiterates Buy Rating on Seaport Therapeutics (SPTX)

Tue, 09 Jun 2026 03:34:25 -0400

Stifel analyst Paul Matteis reiterated a Buy rating and $30.00 price target on Seaport Therapeutics (NASDAQ: SPTX)
The analyst comments: “We're reiterating Buy on SPTX--timelines for their GlyphAllo/SPT-300 and GlyphAgo/ SPT-320 remain on-track. Highlighted in our recent initiation report (LINK), SPTX is leveraging their novel "Glyph" platform to significantly improve PK/bioavailability and/ or safety for two therapies--allopregnanalone and agomelatine--where the mechanism is at least somewhat validated, but there are drug limitations to improve upon. GlyphAllo is the lead program, and the MDD ph2b is enrolling with topline-data expected 1H27--SPTX plans to enroll the full 360 patient target sample size (no longer

Seaport Therapeutics reports positive phase 1 data for GlyphAgo anxiety drug

Tue, 09 Jun 2026 02:00:42 -0400

Seaport Therapeutics Inc. (NASDAQ: SPTX) reported positive results from the multiple-ascending dose portion of its Phase 1 trial for GlyphAgo, an oral prodrug of agomelatine being developed for generalized anxiety disorder.

The seven-day dosing study in healthy volunteers showed GlyphAgo achieved therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce the need for liver function testing. The drug demonstrated consistent safety, tolerability and pharmacokinetic profiles across all trial portions, with no serious adverse events or liver-related safety issues observed.

The Phase 1 trial included 174 participants across single-ascending dose, multiple-ascending dose and crossover portions. Previously reported crossover

Seaport Therapeutics reports positive phase 1 data for GlyphAgo anxiety drug

Tue, 09 Jun 2026 02:00:42 -0400

Seaport Therapeutics Inc. (NASDAQ: SPTX) reported positive results from the multiple-ascending dose portion of its Phase 1 trial for GlyphAgo, an oral prodrug of agomelatine being developed for generalized anxiety disorder.

The seven-day dosing study in healthy volunteers showed GlyphAgo achieved therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce the need for liver function testing. The drug demonstrated consistent safety, tolerability and pharmacokinetic profiles across all trial portions, with no serious adverse events or liver-related safety issues observed.

The Phase 1 trial included 174 participants across single-ascending dose, multiple-ascending dose and crossover portions. Previously reported crossover